Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleFeatured Basic Science Article
Open Access

Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy

Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo and Zhibo Liu
Journal of Nuclear Medicine June 2022, 63 (6) 952-958; DOI: https://doi.org/10.2967/jnumed.121.262533
Mengxin Xu
1Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pu Zhang
1Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jie Ding
2Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junyi Chen
1Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Huo
2Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhibo Liu
1Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Beijing National Laboratory for Molecular Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, China;
3Peking University–Tsinghua University Center for Life Sciences, Beijing, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    (A) Chemical structures of TEFAPI-06 and TEFAPI-07. (B) Competition assays of TEFAPI-06 and TEFAPI-07. (C) Saturation binding assays of radiolabeled TEFAPI-06 and TEFAPI-07. (D) Cellular uptake assays of 68Ga-TEFAPI-06 and 68Ga-TEFAPI-07 in HT-1080-FAP and HT-1080 cells. IC50 = half-maximal inhibitory concentration.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    (A) Dynamic PET imaging of 68Ga-TEFAPI-06 and 68Ga-TEFAPI-07 in healthy NOD/SCID mice. (B) Corresponding blood time–activity curves of 68Ga-TEFAPI-06 and 68Ga-TEFAPI-07.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    (A) PET imaging of 86Y-TEFAPI-06 and 86Y-TEFAPI-07 in PDX-bearing mice. (B) Time–activity curves for tumor and major organs of 86Y-TEFAPI-06 and 86Y-TEFAPI-07.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    (A) PET imaging of 86Y-TEFAPI-06 and 86Y-TEFAPI-07 in HT-1080-FAP and HT-1080 tumor–bearing mice at 24 h after injection. (B) Uptake of 86Y-TEFAPI-06 and 86Y-TEFAPI-07 in HT-1080-FAP and HT-1080 tumors at 24 h after injection. ***P < 0.001.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Biodistribution study of 177Lu-TEFAPI-06 and 177Lu-TEFAPI-07 in pancreatic cancer PDX–bearing mice at 96 h after injection (n = 5).

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Treatment assay of 177Lu-TEFAPI-06 and 177Lu-TEFAPI-07 in pancreatic cancer PDX-bearing mice. (A) Design of therapy protocols and treatment scheme. (B) Tumor growth curve after treatment (n = 7–9 mice for each group). (C) Body weight change after treatment.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1.

    Biodistribution Results for 177Lu-TEFAPI-06 and 177Lu-TEFAPI-07

    177Lu-TEFAPI-06177Lu-TEFAPI-07
    24 h96 h24 h96 h
    OrganMeanSDMeanSDMeanSDMeanSD
    Blood12.321.332.250.685.641.490.510.24
    Pancreas2.010.260.750.422.160.690.530.22
    Spleen3.000.663.661.222.690.871.880.34
    Small intestine2.550.640.610.281.190.260.160.09
    Large intestine1.660.270.530.351.150.330.100.15
    Liver2.980.641.740.573.210.812.310.17
    Kidney3.200.842.660.548.672.3010.163.28
    Stomach1.750.170.540.211.200.450.290.14
    Fat1.860.901.551.171.821.180.480.25
    Muscle1.090.180.450.051.000.370.280.16
    Bone1.320.300.350.201.710.630.180.28
    Lung4.331.441.950.702.580.750.730.28
    Heart3.701.591.510.422.531.190.620.17
    Brain0.370.080.090.030.230.09−0.010.04
    Tumor8.680.737.332.287.872.087.572.68
    • Data are %ID/g.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (6)
Journal of Nuclear Medicine
Vol. 63, Issue 6
June 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo, Zhibo Liu
Journal of Nuclear Medicine Jun 2022, 63 (6) 952-958; DOI: 10.2967/jnumed.121.262533

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
Mengxin Xu, Pu Zhang, Jie Ding, Junyi Chen, Li Huo, Zhibo Liu
Journal of Nuclear Medicine Jun 2022, 63 (6) 952-958; DOI: 10.2967/jnumed.121.262533
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts
  • Blind Image Restoration Enhances Digital Autoradiographic Imaging of Radiopharmaceutical Tissue Distribution
Show more Featured Basic Science Article

Similar Articles

Keywords

  • albumin binder
  • FAP inhibitor
  • Radionuclide Therapy
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire